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The vascular risk attributable to HIV infection is rising. The heterogeneity of the samples
studied is an obstacle to understanding whether HIV is a vascular risk across geographic
regions.
Objective
To test the hypothesis that HIV infection is a vascular risk factor, and that the risk conferred
by HIV varies by geographical region.
Data sources
A systematic search of publications was carried out in seven electronic databases: PubMed,
The Cochrane Library, EMBASE, Web of Science, LILACS, ClinicalTrials.gov, andWHO
International Clinical Trials Registry Platform from inception to July 2015.
Study selection
We included longitudinal studies of HIV+ individuals and their risk of vascular outcomes of
50 HIV+ cases and excluded studies on biomarkers of vascular disease as well as clinical
trials.
Data extraction and synthesis
Data was extracted by one of the authors and independently confirmed by the other two
authors. We used incidence rate (IR), incidence risk ratio (IRR) and hazard ratio (HR) with
their 95% confidence intervals as measures of risk.
Main outcome
All-death, myocardial infarction (MI), coronary heart disease (CHD), any stroke, ischemic
stroke (IS) or intracranial hemorrhage (ICH).
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Results
We screened 11,482 references for eligibility, and selected 117 for analysis. Forty-four
cohorts represented 334,417 HIV+ individuals, 49% from the United States. Compared with
their European counterparts, HIV+ individuals in the United States had higher IR of death
(IRR 1.78, 1.69–1.88), MI (IRR 1.61, 1.29–2.01), CHD (IRR 2.27, 1.92–2.68), any stroke
(IRR 1.94, 1.59–2.38), IS (IRR 1.56, 1.23–1.98), and ICH (IRR 4.03, 2.72–6.14). Compared
with HIV- controls and independent of geographical region, HIV was a risk for death (HR
4.77, 4.55–5.00), MI (HR 1.60, 1.49–1.72), any CHD (HR 1.20, 1.15–1.25), any stroke (HR
1.82, 1.53–2.16), IS (HR 1.27, 1.15–1.39) and ICH (HR 2.20, 1.61–3.02). Use of antiretrovi-
ral therapy was a consistent risk for cardiac outcomes, while immunosuppression and
unsuppressed viral load were consistent risks for cerebral outcomes.
Conclusions
HIV should be considered a vascular risk, with varying magnitudes across geographical and
anatomical regions. We think that strategies to reduce the HIV-related vascular burden are
urgent, and should incorporate the disparities noted here.
Introduction
Vascular disease is the leading cause of global death, [1] and it has become a particular concern
in the aging HIV population. The World Health Organization estimates that approximately 37
million people are currently living with HIV/AIDS. [2] Non-infectious comorbidities have
emerged as important sources of morbidity and mortality in HIV+ populations, [3] with vas-
cular disease being the leading cause of death among older HIV+ individuals. [4] Whether the
rates of vascular disease are a reflection of aging and aging-comorbidities per se or HIV-related
is an area of ongoing investigation. Furthermore, disparities in rates of vascular disease are
influenced by geographical factors that not only reflect greater prevalence of vascular risk fac-
tors but also socioeconomic factors that vary regionally.[5] HIV in the United States (US)
affects predominantly underserved populations, often living in circumstances that may also
influence vascular disease.[6] Additionally, evidence suggests that HIV-related variables such
as immunological factors,[7] use of cART, [8] and co-infection with other viruses may modify
the risk of vascular disease seen in HIV+ populations.[9] Because the prevalence of these con-
founders of risk vary depending on the population studied,[10–12] it is plausible that some of
disparities in vascular risk seen in HIV+ populations may be attributable to geographical
confounders.
Therefore, we conducted a systematic review and a meta-analysis of published medical
literature to assess the risk of death and vascular disease among HIV+ individuals to test the
hypothesis that HIV infection is a vascular risk factor, and that the risks conferred by HIV var-
ies by geographical region.
Methods
Data sources and searches: Our first search was conducted on PubMed on May 26th, 2015
by a librarian (LouF), and 7,203 articles were found. Our second search was carried out in
EMBASE, Web of Science and LILACS, within a week (from July 27th to July 31st). 1,172
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articles were found to be duplicates from our first search, so we carefully excluded them leav-
ing 2,859 new articles, of which 1,500 were from EMBASE, 1,293 fromWeb of Science and 66
from LILACS. Our third search was conducted in The Cochrane Library, ClinicalTrials.gov
andWHO International Clinical Trials Registry Platform on July 29, 2015, and 248 studies
were found. After the exclusion of the non-relevant studies and the duplicates, 37 new articles
remained, of which 31 were from The Cochrane Library, 2 from ClinicalTrials.gov and 4 from
WHO International Clinical Trials Registry Platform. Therefore, a total of 11,482 studies were
screened for inclusion in our meta-analysis (Fig 1, S1 File and S2 File). One publication from a
cohort identified through our search was brought to our attention by one of the study investi-
gators.[13].
Longitudinal studies of HIV+ individuals were selected for analysis. The studies were
included if they met the following criteria: (1) observational study design; (2) sample size 50
HIV+ cases, and (3) all-death, myocardial infarction (MI), any coronary heart disease (CHD),
any stroke, ischemic stroke (IS) or intracranial hemorrhage (ICH) reported as primary out-
come. Studies were excluded if: (1) not about HIV; (2) not about vascular disease; (3) related
to cognition and/or dementia; (4) animal studies; (5) in vitro studies; (6) cross-sectional
design; (7) small samples (< 50 patients); (8) meta-analysis, systematic reviews and reviews;
(9) studies that were not in English, Spanish, French or Portuguese; (10) editorials; (11) studies
exploring only pathogenesis; (12) clinical trials (to improve more representative samples of the
general population with HIV) and (13) studies from before cART era (<1994).
Study Selection: The first screening in each database was carried out by looking at the title
and the abstract of the articles. The second screening consisted of retrieving the full text or
extended abstract from pre-screened citations. One of us (AnaA) independently classified the
studies as appropriate for further consensus review (between AnaA and JosG) to select studies
for this analysis.
Fig 1. Flow diagram of the systematic search.
https://doi.org/10.1371/journal.pone.0176686.g001
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Data extraction and quality assurance: We obtained from each of the selected articles the
demographic, clinical and laboratory data reported by HIV status. We noted whether the
study provided a measure of risk (i.e. Hazard ratios, risk ratio, etc.), and whether the given
measure was adjusted for confounders. If the study did not report measures of risks, we calcu-
lated crude rate ratios with the provided number of events and sample size. We extracted
crude incidence rates when provided. If not provided, we estimated incidence rate and their
confidence intervals with the data provided by the authors. If the author did not provide total
person-year follow-up, we estimated it by multiplying the follow-up time by the number of
subjects and contrasted the estimated incidence rate with the reported in the paper. In the
cohorts where HIV negative controls were included, we prioritized obtaining the adjusted haz-
ard ratios, but if not available, we obtained the unadjusted hazard ratio, the risk ratio, or calcu-
lated the unadjusted hazard ratio as indicated elsewhere.[14] We used exchangeable incidence
rate ratio (IRR), risk ratio, relative risk, with hazard ratios.[15] We noted whether the popula-
tion study reflected first-time event, recurrent events in populations with known vascular dis-
ease, and the geographical region. Finally, we extracted the hazard ratio or risk ratio in cohorts
that included HIV only models.
An ideal study would include a random representative sample of the population of HIV in
the geographical area of study, compared to a representative or random sample from HIV
uninfected controls from the same geographical area. The study must present adjusted hazard
ratios by traditional vascular risk factors and ideally would control not only by the presence or
absence or vascular risk factors, but also by the degree of control as defined by established clin-
ical guidelines or by using continuous longitudinal measurements of the intensity of such vas-
cular risk factors. A good study would include commodity samples (e.g. administrative
datasets, hospital-based, etc.) that included matched (at least by age and sex) HIV- controls,
and that reported hazard ratios adjusting for at least demographics and vascular risk factors
(expressed categorically or with some continuous measurements measured at baseline). A fair
study would report only unadjusted rates of a given outcome.
Data synthesis and Analysis: Demographic, clinical and laboratory data were summarized
with simple averages from all the studies that provided them. When a given study provided
stratified data, a weighted average was obtained accordingly to be able to harmonize with
other studies. Incidence rate and 95% CI (when not provided by the authors) were calculated
from raw data using MedCalc Statistical Software version 16.2.1 (MedCalc Software bvba, Ost-
end, Belgium; https://www.medcalc.org; 2016).
Statistical analysis
Fixed effects were used for all outcomes. Random effects were used to test robustness of
results.[16, 17] The natural logarithm of the HR and their 95% CI for demographic, clinical
and laboratory variables were calculated for each study.[14] The average HR and 95% CI for
each outcome was obtained using Inverse Variance statistical method provided by Review
Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane
Centre, the Cochrane Collaboration, 2014. Heterogeneity was tested only in geographic sub-
groups and it was quantified with Q test and I2. A two-tailed alpha value of 0.05 was used to
determine statistical significance.
Results
a) Characteristics of the HIV populations studied
Forty-four cohorts represented 334,417 HIV+ individuals, 49% from the US (Tables A-C in S1
File). The majority of the studies with extractable data and well-defined vascular outcomes
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came from the US and Europe, which facilitated the comparison between the US and Europe.
Using simple linear regression with each study weighted by their sample size, HIV+ individuals
in the US had a higher mean age (B = 10.0, P = 0.001), were more likely non-white (B = 27.3,
P = 0.005), had viral loads< 1000 copies (B = 5.05, P = 0.001), hepatitis C (B = 24.33, P = 0.01)
or higher CD4 counts (B = 48.1, P = 0.01) than their European counterparts. Among the 11
studies that included HIV- controls, HIV+ were more commonly men, non-white, and had a
higher prevalence of hypertension, diabetes, dyslipidemia, smoking, hepatitis C, drug use, and
baseline cardiac disease (Table D in S1 File).
b) Incidence rate of death and vascular disease in HIV+ versus HIV-
populations (Table 1)
Among HIV+ individuals, the MI incidence was higher than stroke incidence (IRR 1.31, 1.05–
1.63). By defining regions more homogenously, however, HIV+ individuals in the US had a
higher stroke incidence than that of MI (IRR 1.37, 1.15–1.64) but less so in Europe (IRR 1.13,
95% CI 0.89–1.44) and in low-to-middle income countries (IRR 1.33, 95% CI 0.94–1.89.
Among HIV- individuals in the US, the incidence rates of stroke versus MI were similar (IRR
1.09, 0.93–1.28).
Compared with their European counterparts, HIV+ individuals in the US had a higher IRR
for death (1.78, 1.69–1.88), MI (1.61, 1.29–2.01), CHD (2.27, 1.92–2.68), stroke (1.94, 1.59–
2.38), IS (2.46, 1.98–3.07), and ICH (4.03, 2.72–6.14). The same geographic disparity was
noted among HIV- controls so that those in the US had a higher IRR for death (4.56, 4.08–
5.11), MI (1.42, 1.19–1.70), CHD (1.34, 1.14–1.59), stroke (1.43, 1.21–1.71), IS (4.45, 3.37–
5.96), and ICH (6.18, 3.68–11.00) than their uninfected European or Canadian counterparts.
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60.3(45.7–78.1) 81.21(64.03–98.39) N/A 5.3(1.71–12.30) N/A
Abbreviations: N/A, not available
https://doi.org/10.1371/journal.pone.0176686.t001
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c) Outcomes by HIV status (Tables E-K in S1 File)
-Death. HIV infection conferred a four-fold increase in the risk of death compared with
HIV- controls (HR 4.77, 4.55–5.00). The point estimate was the highest in the US, but the sig-
nificance remained similar across geographical regions (Fig 2). Of the six included studies, five
did not adjust for confounders; the only study that did adjust for confounders showed a signif-
icant 4-fold increase risk of death attributable to HIV.[18] The results were heterogeneous (I2
= 98%), but the six individual point estimates were independently significant. Varying the esti-
mation method from fixed effect to random effect did not change the statistical significance
but it reduced the point estimate by 23%.
-Myocardial infarction. HIV+ individuals had a higher risk of MI compared with HIV-
controls (HR 1.60, 1.49–1.72, Fig 3). The seven studies included adjusted for at least sex and
age, and the studies from administrative datasets in the US and Europe also controlled for vas-
cular risks. The results were significant across regions, but the point estimates were lower for
those in the US. The two smallest studies that reported a non-significant increased risk of MI
with HIV studied recurrent MI as outcome. The results were moderately heterogeneous (I2 =
64%), mostly due to the two studies that showed a point estimate greater than two.[19, 20] The
results were insensitive to the effect estimation method.
-Any CHD. Nine studies had data for any CHD, five referring to MI and 4 to CHD. HIV
+ individuals had a higher risk of CHD than HIV- controls (HR 1.20, 1.15–1.25, Fig 4). Taking
out the five studies with MI as outcome reduced significantly the strength of the association
between HIV and CHD, but it remained significant (HR 1.05, 1.00–1.10). Among the four
studies reporting CHD, only one adjusted for multiple confounders, reporting twice the risk of
CHD with HIV.[21] The results were heterogeneous as the point estimate ranged from 1.02 to
2.40 (I2 = 94%). The results were significant across regions, but the point estimates were lower
Fig 2. Risk of death in HIV+ individuals vs. HIV- controls.Red squares represent the point estimate for HIV-related vascular risk by study, and the size of
each red square represents the weight of each study in the average effect size. Horizontal lines across red squares represent the 95% confidence intervals
for the point estimate. The diamonds represent the weighted average point estimate.
https://doi.org/10.1371/journal.pone.0176686.g002
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for those in the US. Furthermore, using a randommodel rather than fixed model increased the
strength of association by 40%.
-Any stroke. HIV+ individuals had a higher risk of any stroke than HIV- controls (HR
1.82, 1.53–2.16, Fig 5). The results were consistent across the Atlantic, with higher point esti-
mates in the US. The risk of stroke among individuals with established CHD was numerically
but not nominally higher among HIV+ individuals. The results were homogenous (I2 = 0%)
and insensitive to the effect estimation method.
-Ischemic stroke. HIV+ individuals had a higher risk of IS than HIV- controls (HR 1.27,
1.15–1.39, Fig 4). The point estimate was higher for the European study included in this com-
parison, but this study used rate ratio (American studies used HR) and adjusted only for age,
sex and country of origin but not for vascular risk factors.[22, 23] The results were homoge-
nous (I2 = 28%) and insensitive to the effect estimation method.
-Intracranial hemorrhage. The risk of hemorrhagic stroke was higher in HIV+ individu-
als compared to uninfected controls (HR 2.20, 1.61–3.02, Fig 4). The risk was adjusted for con-
founders in all studies. The results were homogenous (I2 = 7%) and the point estimate did not
change using a randommodel. The point estimates were higher for the non-American studies
than for the American study included in this outcome.
d) Vascular risks among HIV+ individuals (Tables 2 and 3)
Older age was the more consistent risks for outcomes among HIV+ individuals. While male
sex was a significant predictor of MI (HR 1.97, 1.51–2.57) and CHD (HR 1.76, 1.33–2.32); it
was not for stroke (HR 1.11, 0.83–1.49). Traditional vascular risks predicted MI/CHD and
stroke, but not IS. The study used to extract HR for IS used atrial fibrillation, structural heart
Fig 3. Risk of myocardial infarction in HIV+ individuals vs. HIV- controls.Red squares represent the point estimate for HIV-related vascular risk by
study, and the size of each red square represents the weight of each study in the average effect size. Horizontal lines across red squares represent the 95%
confidence intervals for the point estimate. The diamonds represent the weighted average point estimate.
https://doi.org/10.1371/journal.pone.0176686.g003
HIV and vascular disease
PLOSONE | https://doi.org/10.1371/journal.pone.0176686 May 11, 2017 7 / 15
disease and anticoagulant/antiplatelet together with traditional vascular risks,[23] which con-
founds the role of risk factors into a given stroke etiology.
While the risk of death was higher among cART naïve patients (HR 5.60, 3.18–9.86), the
risk of MI (HR 1.20, 1.09–1.33) was higher with the use of cART, especially abacavir (HR 1.77,
1.50–2.10) and protease inhibitors (HR 1.09 per year of use, 1.08–1.47). While abacavir was
also identified as a risk factor for stroke (HR 2.10, 1.20–3.66), the use of cART or different sub-
types of cART was less consistently reported as a risk factor for IS or ICH. While the role of
CD4 counts was equivocal for MI/CHD, CD4 counts< 200 cells was a risk factor for death
(HR 2.98, 2.67–3.32), stroke (HR 1.91, 1.44–2.54) and ICH (HR 4.61, 2.09–10.2). Similarly, the
risk of MI/CHD due to unsuppressed viral replication is equivocal, while unsuppressed viral
replication is a risk for death (HR 1.65 if>10-100K, 1.50–1.81), stroke (HR 3.97 if> 400 cop-
ies, 1.90–8.31), and IS (HR 1.10 per log, 1.04–1.17). While the use of drug use and hepatitis b
were less consistently related with vascular outcomes, Hepatitis C emerged as a consistent risk
for death (HR 1.74, 1.55–1.96), CHD (HR 3.94, 1.00–15.5) and stroke (HR 1.22, 1.06–1.40).
Discussion
The cumulative evidence presented here suggests that HIV+ individuals have a higher risk of
death and vascular disease than uninfected populations. The results were consistent even in
studies that used adjusted models of good quality and in those that used referent uninfected
populations with similar socioeconomic background.[12, 24, 25] Although there exist unmea-
sured variability in vascular risk factor control and other possible confounders, this deficit in
Fig 4. Risk of any coronary artery disease in HIV+ individuals vs. HIV- controls.Red squares represent the point estimate for HIV-related vascular
risk by study, and the size of each red square represents the weight of each study in the average effect size. Horizontal lines across red squares represent
the 95% confidence intervals for the point estimate. The diamonds represent the weighted average point estimate.
https://doi.org/10.1371/journal.pone.0176686.g004
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Fig 5. Risk of cerebrovascular events in HIV+ individuals vs. HIV- controls.Red squares represent the point estimate for HIV-
related vascular risk by study, and the size of each red square represents the weight of each study in the average effect size.
Horizontal lines across red squares represent the 95% confidence intervals for the point estimate. The diamonds represent the
weighted average point estimate.
https://doi.org/10.1371/journal.pone.0176686.g005
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methodology does not change the public health implication that HIV+ populations are at a
greater risk of vascular disease than uninfected controls. Furthermore, the increased vascular
risk is consistent across geographical regions, which adds strength to our main results. The
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Table 3. Meta-analysis of HIV-related variables and coinfections among HIV infected cohorts.
Outcome cART CD4 count Viral load Drug Use HBV HCV








# studies 1 study 5 studies 4 studies 5 studies - 2 studies
Myocardial
infarction
Any cART: 1.20, 1.09–1.33Abacavir (any):
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Any Coronary
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Any cART: 1.05, 0.57–1.43Abacavir (any):
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1.40
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Ischemic stroke NRTI use: 1.19 (0.51–2.79)NNRTI use: 0.38
(0.19–0.76)PI use: 0.63 (0.30–1.33)
0.97,0.90–1.05









N/A N/A N/A N/A
# studies 1 study 1 study
Abbreviations: N/A, not available.
https://doi.org/10.1371/journal.pone.0176686.t003
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magnitude of the risk, however, differs by region, with greater rates of vascular disease noted
in HIV+ individuals in the US compared to those living in Europe. Similar geographic dispari-
ties were also noted for HIV- controls living in the US compared to those in Europe, and this
disparity is not exclusive to the HIV- controls included in this meta-analysis, but also noted in
studies more representative of the general population in US and Europe.[26, 27] Together,
these data suggest that individuals in the US included in this meta-analysis (predominantly
from matched underserved populations) and in general have poorer vascular health than those
in Europe. The infection with HIV accentuates even further such disparity.
The disparities in risk attributed to HIV may have several explanations. First, the incidence
rates used in our analysis are averages of several years. As the care for those with HIV has
improved, the rates of vascular risk have decreased and the relative risk compared with unin-
fected controls has attenuated. [13, 28–30] Also, because greater risk of vascular events is often
noted after initiation of cART in patients with low CD4 counts compared to starting it when
CD4 counts are higher, [21, 31] more recent event rates may be lower as greater emphasis is
given to start cART earlier in the course of the infection.[32] The higher prevalence of vascular
risk factors among HIV+ individuals included in this study (Table D in S1 File) or HIV+ indi-
viduals in the US (Table L in S1 File) compared to uninfected referent populations may be
another contributor to the disparity in vascular risks. Traditional vascular risks confer a higher
risk of death and vascular disease (Table 3), and thus represent a clear target for intervention.
It is a major limitation that several studies focused on vascular disease did not report rates of
vascular risk factors, and that only a minority of studies reported the degree of control of such
risks, so an even greater proportion of the HIV-related disparity in vascular risk attributable to
traditional vascular risk factors cannot be excluded. Arterial inflammation may also play a role
in HIV-related vascular disease. For example, evidence exists of arterial inflammation in the
aorta and brain arteries accompanied by activation of soluble blood biomarkers of inflamma-
tion, which relates to biomarkers of vascular risk.[33, 34] Accelerated atherosclerosis has been
documented in HIV+ individuals as documented by a higher carotid intima-media thickness
and coronary artery calcium rate of progression mostly driven by traditional vascular risk fac-
tors, with a lesser role for higher viral loads and CD4 nadir< 200.[35, 36] Determining the
triggers for arterial inflammation may offer new therapeutic venues in this population.
Coronary heart disease is predominantly due to atherosclerosis, and the risk is typically
related to traditional vascular risk factors and cART, especially abacavir (Table 3).[37] Stroke
during HIV infection, on the other hand, is a heterogeneous disease where traditional vascular
risk factors play only a partial role. For example, the Framingham risk score is a better predic-
tor of biomarkers for CHD [38] than for stroke risk among HIV+ individuals.[39] Studies that
define stroke more broadly do reproduce known associations between stroke and vascular risk
factors among those with HIV, but reports that disclose the mechanisms of stroke in more
details provide etiologies not typically found in cardiac disease, such as hypercoagulable state,
vasculitis, and HIV vasculopathy.[40–43] These data suggest the need for greater discrimina-
tion in mechanistic studies between cerebral and cardiac outcomes, so that targeted preventive
measures can be appropriately applied.
Results of this study should be interpreted in light of the following limitations. The popula-
tions studied are heterogeneous, most outcomes are obtained from administrative datasets,
and adjudication of vascular events was usually not confirmed by chart review. The studies we
included over-represent HIV+ populations on cART and results may not apply to the entire
HIV+ population. However, given that HIV suppression, immune competence, and access to
care protect against death and vascular events, vascular risks of HIV may be even greater for
these underrepresented in this study. This bias is not a minor issue: in the US alone, more than
1.2 million people live with HIV and over 50,000 new cases of HIV infection are diagnosed
HIV and vascular disease
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each year.[44] Of this population, 14% are unaware of their diagnosis, 60% do not engage in
care, and only a minority received cART or achieve viral suppression, with the lowest rate of
viral suppression noted in the youngest cohort. Because one out of four newly HIV-infected
individuals and over 100,000 currently living with HIV are between 13–24 years old, [45]
studying HIV-related vascular disease represents a major public health challenge due to high
indirect costs of vascular disease in the young such as longer years of lost productivity and pre-
mature death attributable to vascular disease.
Supporting information
S1 File. Table A:Demographic, clinical and immunological characteristics of HIV cohorts
studied at baseline enrollment Table B:General characteristics of the studies including HIV
+ cases compared with HIV- controls Table C:Weighted averages of study characteristics of
the HIV samples studied across geographical regions Table D:Difference in demographic and
clinical characteristics in HIV+ compared with HIV- cases Table E: All-death risks among
HIV+ samples Table F:Myocardial infarction risks among HIV+ individuals Table G: Coro-
nary Heart Disease risks among HIV+ individuals Table H: Cerebrovascular risks among HIV
+ individuals Table I: Vascular death risks among HIV+ individuals Table J: Any vascular dis-
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